Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Exploratory Clinical Study of the Safety, Tolerability and Initial Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

NCT06045585 is registered in ClinicalTrials.gov with Guangdong Second Provincial General Hospital as lead sponsor.

NCT NCT06045585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06045585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Exploratory Clinical Study of the Safety, Tolerability and Initial Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Lead sponsor
Guangdong Second Provincial General Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
August 18, 2023
Completion date
December 31, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory b-cell lymphoma